Thymidine kinase-1 as a biomarker in breast cancer: estimating prognosis and early recognition of treatment resistance
Author:
Affiliation:
1. “Sandro Pitigliani” Medical Oncology Department, Hospital of Prato, Prato, Italy
2. “Sandro Pitigliani” Translational Research Unit, Hospital of Prato, Prato, Italy
Publisher
Future Medicine Ltd
Subject
Biochemistry (medical),Clinical Biochemistry,Drug Discovery
Link
https://www.futuremedicine.com/doi/pdf/10.2217/bmm-2020-0072
Reference28 articles.
1. Palbociclib and Letrozole in Advanced Breast Cancer
2. Ribociclib as First-Line Therapy for HR-Positive, Advanced Breast Cancer
3. MONARCH 3: Abemaciclib As Initial Therapy for Advanced Breast Cancer
4. The cyclin-dependent kinase 4/6 inhibitor palbociclib in combination with letrozole versus letrozole alone as first-line treatment of oestrogen receptor-positive, HER2-negative, advanced breast cancer (PALOMA-1/TRIO-18): a randomised phase 2 study
5. Cyclin E1 Expression and Palbociclib Efficacy in Previously Treated Hormone Receptor–Positive Metastatic Breast Cancer
Cited by 7 articles. 订阅此论文施引文献 订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献
1. Development of a gold nanoparticle-based lateral flow immunochromatographic assay for the rapid and quantitative detection of thymidine kinase 1 in human serum;Journal of Pharmaceutical and Biomedical Analysis;2024-08
2. Multiplexed sequential imaging in living cells with orthogonal fluorogenic RNA aptamer/dye pairs;Nucleic Acids Research;2024-06-26
3. Strand displacement–triggered FRET nanoprobe tracking TK1 mRNA in living cells for ratiometric fluorimetry of nucleic acid biomarker;Microchimica Acta;2024-06-13
4. Transcription factor Dp-1 knockdown downregulates thymidine kinase 1 expression to protect against proliferation and epithelial-mesenchymal transition in cervical cancer;Functional & Integrative Genomics;2023-09-16
5. Association between Systemic Immune-Inflammation Indices, Serum TK1 Levels and Clinical Prognosis in Gastric Cancer Patients;J BIOL REG HOMEOS AG;2023
1.学者识别学者识别
2.学术分析学术分析
3.人才评估人才评估
"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370
www.globalauthorid.com
TOP
Copyright © 2019-2024 北京同舟云网络信息技术有限公司 京公网安备11010802033243号 京ICP备18003416号-3